Jazz Pharmaceuticals PLC | Mutual Funds
Mutual Funds that own Jazz Pharmaceuticals PLC
Putnam Capital Spectrum Fund
2,842,521
4.71%
-1,775,756
24.19%
06/30/2018
Vanguard Total Stock Market Index Fund
1,432,632
2.37%
1,380
0.03%
07/31/2018
Vanguard Mid Cap Index Fund
1,352,918
2.24%
10,824
0.22%
07/31/2018
Putnam Equity Spectrum Fund
1,068,954
1.77%
-305,582
21.89%
06/30/2018
Fidelity Puritan Fund
898,500
1.49%
0
0.54%
07/31/2018
Vanguard Extended Market Index Fund
794,735
1.32%
2,400
0.19%
07/31/2018
iShares Nasdaq Biotechnology ETF
693,651
1.14%
-9,072
1.21%
09/06/2018
Fidelity Funds SICAV - America Fund
644,695
1.07%
-53
2.08%
05/31/2018
CREF Stock Account
636,174
1.05%
155,181
0.08%
03/31/2018
Fidelity Series Stock Selector Large Cap Value Fund
556,595
0.92%
-45,400
0.96%
07/31/2018
| Address |
Waterloo Exchange
Dublin Dublin 4
Ireland
|
|
Employees
|
- |
| Website |
http://www.jazzpharma.com |
| Updated |
07/08/2019 |
| Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. |
